WO2008114114A3 - Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition - Google Patents

Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition Download PDF

Info

Publication number
WO2008114114A3
WO2008114114A3 PCT/IB2008/000615 IB2008000615W WO2008114114A3 WO 2008114114 A3 WO2008114114 A3 WO 2008114114A3 IB 2008000615 W IB2008000615 W IB 2008000615W WO 2008114114 A3 WO2008114114 A3 WO 2008114114A3
Authority
WO
WIPO (PCT)
Prior art keywords
ophthalmic condition
adp
ribose
poly
treating ophthalmic
Prior art date
Application number
PCT/IB2008/000615
Other languages
French (fr)
Other versions
WO2008114114A2 (en
Inventor
Michael Niesman
Jr David Decker Eveleth
Original Assignee
Pfizer Prod Inc
Michael Niesman
Jr David Decker Eveleth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Michael Niesman, Jr David Decker Eveleth filed Critical Pfizer Prod Inc
Publication of WO2008114114A2 publication Critical patent/WO2008114114A2/en
Publication of WO2008114114A3 publication Critical patent/WO2008114114A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention generally relates to use of 8-f luoro-2- {4- [ (methylamino) methyl] phenyl} -1,3,4, 5-tetrahydro-6H-azeρino [5,4, 3-cd] indol- 6 -one, represented by formula (1) or a pharmaceutically acceptable salt thereof for treating ophthalmic condition selected from the group consisting of glaucoma, diabetic macular edema, uveitis, retinitis, retinopathies, choroidal neovascularization, ocular angiogenesis, and age related macular degeneration.
PCT/IB2008/000615 2007-03-16 2008-03-05 Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition WO2008114114A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89517607P 2007-03-16 2007-03-16
US60/895,176 2007-03-16

Publications (2)

Publication Number Publication Date
WO2008114114A2 WO2008114114A2 (en) 2008-09-25
WO2008114114A3 true WO2008114114A3 (en) 2009-02-05

Family

ID=39589718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/000615 WO2008114114A2 (en) 2007-03-16 2008-03-05 Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition

Country Status (1)

Country Link
WO (1) WO2008114114A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754072B2 (en) 2010-02-12 2014-06-17 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CN104592232A (en) * 2015-03-02 2015-05-06 中国药科大学 8,9-dihydro-2,4,7,9a-tetrazine benyoayulene-6(7H)-ketone derivatives
US20190049465A1 (en) * 2016-02-06 2019-02-14 Georgetown University Compositions and methods for the diagnosis and treatment of age-related macular degeneration
MX2020007060A (en) 2018-01-05 2020-11-11 Cybrexa 1 Inc Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues.
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MX2022000450A (en) 2019-07-10 2022-04-25 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics.
KR20230002487A (en) 2020-04-28 2023-01-05 리젠 파마슈티컬스 아게 Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
MX2023011793A (en) 2021-04-08 2023-10-12 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380193B1 (en) * 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US20040229895A1 (en) * 2003-02-28 2004-11-18 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
WO2006033006A2 (en) * 2004-09-22 2006-03-30 Pfizer Inc., Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2006033007A2 (en) * 2004-09-22 2006-03-30 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380193B1 (en) * 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US20040229895A1 (en) * 2003-02-28 2004-11-18 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
WO2006033006A2 (en) * 2004-09-22 2006-03-30 Pfizer Inc., Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2006033007A2 (en) * 2004-09-22 2006-03-30 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHIOU SHIH-HWA ET AL: "Apoptosis of human retina and retinal pigment cells induced by human cytomegalovirus infection", OPHTHALMIC RESEARCH, vol. 34, no. 2, March 2002 (2002-03-01), pages 77 - 82, XP008097286, ISSN: 0030-3747 *
LING ZHENG ET AL: "Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB", DIABETES, vol. 53, no. 11, November 2004 (2004-11-01), pages 2960 - 2967, XP008097276, ISSN: 0012-1797 *
OBROSOVA IRINA G ET AL: "Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 14, no. 1, July 2004 (2004-07-01), pages 55 - 64, XP008097285, ISSN: 1107-3756 *
PAQUET-DURAND FRANCOIS ET AL: "Excessive activation of Poly(ADP-Ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse", JOURNAL OF NEUROSCIENCE, vol. 27, no. 38, September 2007 (2007-09-01), pages 10311 - 10319, XP002502749, ISSN: 0270-6474 *
THOMAS, HUW D. ET AL: "Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial", MOLECULAR CANCER THERAPEUTICS , 6(3), 945-956 CODEN: MCTOCF; ISSN: 1535-7163, 2007, XP008097275 *
ZHANG X ET AL: "Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression", CURRENT EYE RESEARCH 200505 GB, vol. 30, no. 5, May 2005 (2005-05-01), pages 395 - 403, XP008097284, ISSN: 0271-3683 *

Also Published As

Publication number Publication date
WO2008114114A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2008114114A3 (en) Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
WO2006042329A3 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
WO2005051328A3 (en) Amelioration of macular degeneration and other ophthalmic diseases
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
WO2006059357A3 (en) Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization
JP2015025011A5 (en)
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2008140051A1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007011875A3 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
WO2008107481A8 (en) 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2009036338A3 (en) Methods for addressing ocular diseases through interference with the wnt signaling pathway
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
WO2008000469A3 (en) Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom
WO2007075720A3 (en) Topical mecamylamine formulations for ocular administration and uses thereof
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2009041566A1 (en) Preventive or remedy for posterior eye diseases containing quinazolinone derivative or quinoxaline derivative as the active ingredient
JP2010514733A5 (en)
WO2005105778A3 (en) 4-amino-5-cyanopyrimidine derivatives
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719311

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08719311

Country of ref document: EP

Kind code of ref document: A2